Dr Aseem Malhotra: Why heart drugs hide a bigger story

Malhotra argues that healthcare has become dominated by pharmacological solutions despite strong evidence that lifestyle changes—diet, movement, sleep, stress reduction, and social connection—prevent and even reverse chronic diseases, especially heart disease. Prescribed medications are estimated to be the third leading cause of death globally, largely because doctors rely on evidence distorted by commercial interests and exaggerated benefit/safety claims.

After initially endorsing COVID vaccines and taking them himself, Malhotra says reanalysis of the original Pfizer and Moderna trials (published in Vaccine) suggests a serious adverse event rate of about 1 in 800—higher, he argues, than the risk of hospitalization from COVID during the early phase for many—and far above historic thresholds that led to other vaccines being withdrawn (e.g., 1 in 10,000 or 1 in 100,000 harms). He links this to excess cardiac events, whistleblower reports of vascular inflammation in vaccinated patients, and pharmacovigilance data with unprecedented yellow card reports, concluding there should have been at least a suspension and full re‑evaluation.

Malhotra highlights that the UK’s MHRA receives about 86% of its funding from pharmaceutical companies and that key expert voices guiding organizations like the British Heart Foundation have substantial pharma ties. He argues this undermines claims of independence and helps explain why negative or uncomfortable findings—for instance, on vaccine harms or limitations of statins—are minimized or ignored, while commercially favorable narratives dominate.

He explains that LDL cholesterol is mostly genetically determined and not a reliable predictor of heart disease for the vast majority of people. Earlier cholesterol-lowering drugs reduced LDL without reducing heart attacks; statins appear helpful mainly via anti-inflammatory and anti-clotting effects. For someone without previous heart disease, the best case (industry-sponsored data) is about a 1 in 100 chance of preventing a non-fatal heart attack or non-disabling stroke over 5 years, with no survival benefit. After a heart attack, benefits are larger but still modest (about 1 in 39 avoiding another heart attack; 1 in 83 living longer), and median life-extension is roughly 4.2 extra days over 5 years—numbers most patients are never told.

Rather than LDL alone, Malhotra emphasizes insulin resistance—driven by excess sugar, ultra-processed foods, chronic stress, poor sleep, and inactivity—as the central driver of atherosclerosis and cardiovascular events. Simple markers of metabolic health (waist size, triglycerides, HDL, blood pressure, and HbA1c) predict risk far better; in the US only about 1 in 8 adults have all five in the healthy range. Improving diet (real food, minimal ultra-processed products, more plants, nuts, seeds, olive oil, oily fish) could, he says, halve global heart disease deaths within a year.